Reproxalap ophthalmic solution 0.25% reached the primary endpoint in a second phase 3 dry eye chamber trial, according to Aldeyra Therapeutics.

Church & Dwight Co. reports soft sales, retail headwinds, and a $30M tariff burden despite offset efforts. Find out why CHD ...

Northwestern Medicine investigators have developed first-of-its-kind eyedrops that use synthetic nanoparticles to help the ...

Treatment with cyclosporine A 0.1% can reduce ocular surface temperature in patients with dry eye disease and meibomian gland ...

Glaucoma is a complex eye condition that damages the optic nerve over time. If untreated, the disease can cause permanent ...

On the social media platform, women are claiming that Preparation H is a miracle fix for puffy eyes, saying that it ...

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The big question for all of us is, how long will this last? And at this point, it’s very difficult to say," Clorox CEO Linda ...

Stay updated on stock market movers as investors brace for earnings reports and rate decisions. Explore key insights on ...

U.S. stocks are sinking Tuesday as AI mania on Wall Street loses more steam and as more companies scrub their forecasts for ...

From furniture that's seen better days to DIY backsplashes to effortless weed removal — your home is about to be revived.

Consumer products giant Clorox (NYSE:CLX) in Q1 CY2025, with sales falling 8% year on year to $1.67 billion. Its non-GAAP ...